Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial.
COVID-19
atorvastatin
pneumonia
treatment
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
04
03
2022
received:
04
12
2021
accepted:
09
03
2022
pubmed:
12
3
2022
medline:
21
5
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
As statins decrease the progression of sepsis and its related mortality, this study aimed to evaluate the effect of atorvastatin on survival and symptom improvement in hospitalized patients with COVID-19. This randomized controlled trial was performed on 156 hospitalized patients with COVID-19 in Bojnourd city in 2021. Patients were randomly divided into comparison (standard therapy: hydroxychloroquine + Kaletra®) and intervention groups (atorvastatin 20 mg, SD, plus standard therapy). The main outcomes were the rate of symptom improvement, duration of hospitalization, need for intubation, and mortality rate. In this study, seven patients died, two patients (2.6%) in the comparison group and five (6.6%) in the intervention group. The mean hospitalization days (p = 0.001), the pulse rate (p = 0.004), and the frequency of hospitalization in the ICU ward (18.4% vs. 1.3%) were longer and greater in the intervention group. The remission probability in the comparison group was greater (p = 0.0001). The median hospitalization days in the intervention group was longer (p < 0.001) and remission in the comparison group occurred 1.71 times sooner (hazard ratio = 1.70, 95% confidence interval = 1.22-2.38, p = 0.002). Totally, adding atorvastatin to the standard regime in this study increased hospitalization days and imposed negative effects on symptom improvement in hospitalized patients with COVID-19.
Identifiants
pubmed: 35274326
doi: 10.1002/jmv.27710
pmc: PMC9088596
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3160-3168Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2
pubmed: 32674818
Pharmacotherapy. 2020 May;40(5):484-486
pubmed: 32267560
Front Psychiatry. 2019 Mar 05;10:103
pubmed: 30890971
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
PLoS Biol. 2011 Mar;9(3):e1000598
pubmed: 21408089
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1137-1152
pubmed: 32430617
Travel Med Infect Dis. 2021 Mar-Apr;40:101976
pubmed: 33476809
Diabetes Metab. 2021 Mar;47(2):101202
pubmed: 33091555
Exp Physiol. 2008 May;93(5):519-27
pubmed: 18310257
J Lipid Res. 1992 Nov;33(11):1569-82
pubmed: 1464741
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423
pubmed: 30948970
Int J Clin Pharmacol Ther. 2007 Jun;45(6):319-27
pubmed: 17595889
AIDS. 2016 Jan;30(2):171-83
pubmed: 26645604
Transl Med Commun. 2021;6(1):3
pubmed: 33521322
PLoS One. 2021 Sep 10;16(9):e0256899
pubmed: 34506533
J Infect Dis. 2020 Mar 16;221(7):1079-1087
pubmed: 31605489
Int J Cardiol Heart Vasc. 2021 Oct;36:100875
pubmed: 34541293
Eur J Clin Invest. 2020 Mar;50(3):e13209
pubmed: 32003000
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Recent Pat Inflamm Allergy Drug Discov. 2009 Nov;3(3):167-76
pubmed: 19663775
Eur Heart J. 2006 Dec;27(24):2945-55
pubmed: 17012299
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Cardiovasc Drugs. 2008;8(6):373-418
pubmed: 19159124
Am J Respir Crit Care Med. 2019 Nov 15;200(10):1282-1293
pubmed: 31206313
Immunology. 2018 May;154(1):69-75
pubmed: 29392731
Am J Respir Crit Care Med. 2009 Jun 15;179(12):1107-14
pubmed: 19324974
Antimicrob Agents Chemother. 2001 Apr;45(4):1231-7
pubmed: 11257039
Elife. 2020 Nov 09;9:
pubmed: 33164751
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Biochem Pharmacol. 2015 Feb 1;93(3):343-51
pubmed: 25482567
Iran Biomed J. 2012;16(2):59-67
pubmed: 22801278
J Med Virol. 2022 Jul;94(7):3160-3168
pubmed: 35274326
Autoimmun Rev. 2003 Oct;2(6):332-8
pubmed: 14550874
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Am J Cardiol. 2020 Dec 1;136:149-155
pubmed: 32946859
Nat Commun. 2021 Feb 26;12(1):1325
pubmed: 33637713
Pediatr Crit Care Med. 2013 Nov;14(9):e438-41
pubmed: 24226567
BMJ. 2022 Jan 7;376:e068407
pubmed: 34996756